VisionQuest Biomedical LLC

Company Profile

**Industry Sector:** Medical Devices

**Company Overview:** VisionQuest Biomedical is a biomedical research and development (R&D) company founded in 2007 with the objective of bringing affordable medical devices to the ophthalmic and diabetes care markets with the goal of ending blindness due to diabetes by 2020. VisionQuest's mission is to become a leading innovative medical device company.

**Target Market(s):** Insurance companies, primary care physicians, endocrinologists, reference laboratories, pharmacy clinics.

Key Value Drivers

**Technology:** VisionQuest has developed the i-RxCam, a retinal imaging and automatic disease screening camera which provides low-cost, easy to use, on-the-spot and superior quality eye disease screening for diabetics. Our IP is protected by a patent awarded in 2013 and a pending patent submitted in 2014.

**Competitive Advantage:** Existing solutions to this problem, such as conventional retinal cameras, are expensive and require an eye care professional to interpret the images they produce. The i-RxCam does not require this interpretation and is the only retinal camera that has embedded software for automatic image quality assessment and diabetic eye disease screening.

**Plan & Strategy:** The i-RxCam will be sold to PCP practice groups and pharmacies using distribution channels from business partners. We will also target the insurance companies that are in need of preventive care.

Product Pipeline

1. **DR-RACS:** Our automatic diabetic eye disease screening software can be used as a stand-alone product compatible with existing retinal cameras on the market.

2. **CARV:** Our "Computer Assisted Retinal Vasculature" software can detect signs of retinal abnormalities due to cardiovascular disease.

3. **NeoScan:** Software for detecting retinopathy of prematurity, the biggest cause of blindness in infants.

Management

**Leadership:** VisionQuest was founded by Dr. Peter Soliz (PhD), who has over 20 years of experience in the medical device R&D field. He is joined by Dr. Simon Barriga (PhD), President, Dr. Wendall Bauman (MD), Chief Medical Officer, and Dr. Gilberto Zamora (PhD), Director of Clinical Operations. This team has developed and successfully commercialized multiple ophthalmic technologies. Their diabetic retinopathy screening program has reached over 25,000 diabetics in the US and Mexico in the last three years.